Vincerx Pharma Reports Second Quarter 2024 Financial Results
August 08, 2024 16:30 ET
|
Vincerx Pharma, Inc.
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected...
Global Cooling Tower Market Report 2024-2029: Power Generation Segment and Asia-Pacific Accounted for Largest Shares of Cooling Tower Market in 2023
July 15, 2024 06:42 ET
|
Research and Markets
Dublin, July 15, 2024 (GLOBE NEWSWIRE) -- The "Global Cooling Tower Market by Type (Evaporative, Dry, Hybrid), Design (Natural, Mechanical), Construction Material (Concrete, Steel, FRP, Wood), Flow...
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
June 26, 2024 09:15 ET
|
Cyclacel
NOTICE OF INTENTION TO GRANT OF NEW EUROPEAN PATENT
COVERING PLOGOSERTIB PHARMACEUTICAL COMPOSITIONS
- Lengthens Patent Exclusivity to August 2040
Basilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma Foundation
June 20, 2024 01:15 ET
|
Basilea Pharmaceutica AG
Allschwil, 20. Juni 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren...
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
June 20, 2024 01:15 ET
|
Basilea Pharmaceutica AG
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...
Seeking Hope Amidst the Infertility Crisis: Vitaleon Pharma’s BGP-15 Molecule Promises a Better Future
June 06, 2024 16:56 ET
|
Vitaleon Pharma
Amsterdam, The Netherlands, June 06, 2024 (GLOBE NEWSWIRE) -- The demographic landscape is facing a significant challenge globally: fertility rates have been consistently below replacement levels...
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024 16:15 ET
|
Vincerx Pharma, Inc.
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug...
Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 - Groundbreaking Advances in PLK Targeted Therapies Promise to Revolutionize Treatment for Cancer and Other Diseases
April 29, 2024 06:53 ET
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's...
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 08, 2024 16:30 ET
|
Vincerx Pharma, Inc.
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic...
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024 16:31 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...